Cost-effectiveness Analysis on Five Regimens of Antibacterial Drug Therapy in the Treatment of Community Acquired Pneumonia / 中国药房
China Pharmacy
; (12)1991.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-527229
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:
To evaluate the cost-effectiveness of five regimens of antibacterial drug therapy in the treatment of community acquired pneumonia.METHODS:
A retrospective study was conducted, in which a total of 128 cases with pneumonia were enrolled and randomly assigned to receive each of the following 5 therapies,cefoperazone sodium/ sulbactam sodium(Group A),levofloxacin(Group B),amoxicillin/ clavulanate potassium(Group C),azithromycin plus ceftazidime(Group D),and cefoxitin(Group E),the therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the five groups.RESULTS:
The costs of the five regimens were 2 137.0 yuan, 1 393.0 yuan, 1 152.5yuan, 2 044.2 yuan and 1 827.0 yuan, respectively;The effective rates were 85.2%, 86.6%, 80.6%, 89.6% and 78.5%, respectively;The cost-effectiveness ratios were 25.08 , 16.09, 14.30, 22.82 and 23.27, respectively; As compared with group C, the incremental cost-effectiveness ratios of the other four groups were 214.02,40.08, 99.08 and —321.19, respectively.CONCLUSION:
The therapy of amoxicillin/ potassium clavulanate is superior to the other regimes in the treatment of community acquired pneumonia.
Full text:
Available
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 4: Health financing
Database:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
/
Observational study
Language:
Chinese
Journal:
China Pharmacy
Year:
1991
Document type:
Article